A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease
Recruiting · NCT07821658 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-09-16 | NCT07821658 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eisai Inc. | 40 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Eisai Trial Site #1 | Nutley | United States | 5 |